A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Mucocutaneous Manifestations of Behcet's Syndrome
Phase of Trial: Phase 0
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Behcet's syndrome; Genital ulcer; Oral ulcer
- Focus Therapeutic Use
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 12 Dec 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.